top of page

Regulation of Nitrosamines in Pharmaceuticals

Despite the considerable efforts invested by global regulatory authorities in evaluating the safety and efficacy of drugs for their citizens, uncertainties still persist. One such concern is the presence of nitrosamines as impurities in pharmaceutical products. Despite rigorous testing and stringent regulations, the emergence of nitrosamines underscores the complexity of ensuring pharmaceutical safety and highlights the ongoing challenges faced by regulatory agencies worldwide.

In recent years, the pharmaceutical industry has faced increasing scrutiny surrounding the presence of nitrosamines in medications. Nitrosamines, known carcinogens, have prompted global regulatory agencies to tighten their oversight to ensure the safety and quality of pharmaceutical products. Understanding the evolving landscape of nitrosamine regulation is crucial for pharmaceutical companies to maintain compliance and uphold public health standards worldwide.

The Emergence of Nitrosamines as a concern in Pharmaceuticals

Nitrosamines are chemical compounds that can form unintentionally during the manufacturing process of pharmaceuticals, primarily through reactions involving certain raw materials or chemical intermediates. These compounds, including N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), have been detected in various medications, particularly those belonging to the class of angiotensin II receptor blockers (ARBs) and other drugs containing secondary or tertiary amines.

Types of Nitrosamines commonly found in Pharmaceuticals

Nitrosamines encompass a diverse group of compounds characterized by the presence of a nitroso group (NO) bonded to an amine group (NH2). Some common types of nitrosamines found in pharmaceuticals include:

  • N-Nitrosodimethylamine (NDMA): NDMA is one of the most well-known nitrosamines and has been detected as an impurity in various pharmaceutical products. It is classified as a probable human carcinogen and is typically formed from the reaction of dimethylamine with nitrites or nitrosating agents.

  • N-Nitrosodiethylamine (NDEA): Similar to NDMA, NDEA is another nitrosamine impurity detected in pharmaceuticals. It is formed from the reaction of diethylamine with nitrites or nitrosating agents and is also classified as a probable human carcinogen.

  • N-Nitrosomorpholine (NMOR): NMOR is a nitrosamine compound that can arise from the reaction of morpholine with nitrites or nitrosating agents. It has been identified as an impurity in certain pharmaceutical products.

  • N-Nitrosopiperidine (NPIP): NPIP is derived from the reaction of piperidine with nitrites or nitrosating agents. It has been found as an impurity in some pharmaceutical formulations.

  • N-Nitrosomethylamine (NMEA): NMEA is another nitrosamine compound that may be present as an impurity in pharmaceuticals. It is formed from the reaction of methylamine with nitrites or nitrosating agents.

These are just a few examples of nitrosamines commonly encountered in pharmaceuticals. It's important for regulatory authorities and pharmaceutical manufacturers to monitor and control the presence of these impurities to ensure the safety and quality of drug products.

Possible Sources of Nitrosamines in Pharmaceuticals

Nitrosamines can originate from various sources in pharmaceuticals, including:

  • Manufacturing processes: Nitrosamines may form as byproducts during the synthesis or production of certain pharmaceutical ingredients or drug products. For example, they can be unintentionally generated during chemical reactions involving amines and nitrosating agents under certain conditions.

  • Raw materials: Contaminated raw materials used in drug manufacturing, such as starting materials, reagents, solvents, or excipients, can introduce nitrosamine impurities into pharmaceutical products.

  • Packaging materials: Nitrosamines can leach into drug products from packaging materials, especially when there is direct contact between the drug formulation and packaging components containing nitrosamine precursors or contaminants.

  • Environmental factors: External environmental factors, such as air pollution, water contamination, or exposure to nitrosamine-containing substances in the environment during manufacturing, storage, or transportation, can also contribute to the presence of nitrosamines in pharmaceuticals.

  • Interactions during storage: Chemical interactions between drug substances and other compounds present in the formulation or storage conditions, such as exposure to heat, light, or certain chemicals, may lead to the formation of nitrosamines over time.

Overall, identifying and mitigating these sources of nitrosamine contamination is crucial to ensure the safety and quality of pharmaceutical products.

Global Regulatory Response

Regulatory agencies worldwide have responded swiftly to address the presence of nitrosamines in pharmaceuticals. The United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and other regulatory bodies have issued guidelines, recommendations, and directives to mitigate the risks associated with nitrosamine contamination.

Allowed Limits for Nitrosamines in Pharmaceuticals

The allowed limits for individual nitrosamines can vary depending on the specific regulatory authority and the type of product. For pharmaceuticals, regulatory agencies typically set specific limits for individual nitrosamines based on available toxicological data and risk assessments.

For example, the European Medicines Agency (EMA) has established specific limits for certain nitrosamines in pharmaceutical products. In July 2020, EMA recommended limits for nitrosamine impurities in sartan blood pressure medicines, with a maximum acceptable intake for nitrosamine impurities of 26.5 nanograms per day.

Similarly, the United States Food and Drug Administration (FDA) has set interim acceptable intake limits for nitrosamine impurities in certain drug products. For example, the FDA's interim acceptable intake limit for NDMA (N-nitrosodimethylamine) in ranitidine (Zantac) is 96 nanograms per day.

Risk Evaluation for Nitrosamines in Pharmaceuticals

Risk evaluation for nitrosamines in pharmaceuticals is a critical aspect of ensuring patient safety and regulatory compliance. By following a systematic approach to identify, assess, and mitigate risks associated with nitrosamine impurities, pharmaceutical companies can help safeguard the health of patients and maintain the quality and integrity of their products. Risk evaluation for nitrosamines in pharmaceuticals involves assessing the potential harm posed by the presence of these compounds in medications. This process typically includes several key steps:

  • Identification of Nitrosamine Impurities: The first step is to identify the presence of nitrosamines in pharmaceutical products. This may involve conducting routine testing and analysis of raw materials, drug substances, and finished products.

  • Quantification of Nitrosamine Levels: Once nitrosamines are detected, the next step is to quantify their levels to determine the extent of contamination. This helps assess the potential risk to patients and prioritize corrective actions.

  • Risk Assessment: Risk assessment involves evaluating the potential health hazards associated with exposure to nitrosamines. This includes considering factors such as the potency of the nitrosamine compound, the route of administration, the duration of exposure, and the population at risk (e.g., pediatric patients, elderly patients, etc.).

  • Determination of Acceptable Limits: Regulatory agencies typically establish acceptable limits for nitrosamine impurities in pharmaceuticals based on risk assessment data. These limits help guide manufacturers in ensuring that their products meet safety standards.

  • Mitigation Strategies: Based on the risk assessment findings, manufacturers may implement various mitigation strategies to reduce or eliminate nitrosamine impurities. This may include process modifications, changes in raw material sourcing, and improvements in manufacturing practices.

  • Ongoing Monitoring and Surveillance: Continuous monitoring and surveillance are essential to ensure that nitrosamine levels remain within acceptable limits over time. This may involve periodic testing of samples from different batches of pharmaceutical products and ongoing evaluation of manufacturing processes.

  • Regulatory Compliance: Finally, manufacturers must ensure compliance with regulatory requirements related to nitrosamine impurities. This includes adhering to guidelines and regulations set forth by regulatory agencies such as the FDA, EMA, and others.

It's important for pharmaceutical manufacturers to ensure that their products comply with these regulatory limits to protect public health and safety. Additionally, ongoing monitoring and risk assessment are essential to address any emerging concerns related to nitrosamine impurities in pharmaceuticals.

Artixio specializes in regulatory compliance and can assist pharmaceutical companies in navigating the complex landscape of nitrosamine regulation. Contact us at to learn more about how we can help ensure your products meet regulatory requirements and prioritize patient safety.


bottom of page